Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies

Stephen M Condon; Yasuhiro Mitsuuchi; Yijun Deng; Matthew G LaPorte; Susan R Rippin; Thomas Haimowitz; Matthew D Alexander; Pavan Tirunahari Kumar; Mukta S Hendi; Yu-Hua Lee; Christopher A Benetatos; Guangyao Yu; Gurpreet Singh Kapoor; Eric Neiman; Martin E Seipel; Jennifer M Burns; Martin A Graham; Mark A McKinlay; Xiaochun Li; Jiawei Wang; Yigong Shi; Rebecca Feltham; Bodhi Bettjeman; Mathew H Cumming; James E Vince; Nufail Khan; John Silke; Catherine L Day; Srinivas K Chunduru

Journal article

Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies

Stephen M Condon, Yasuhiro Mitsuuchi, Yijun Deng, Matthew G LaPorte, Susan R Rippin, Thomas Haimowitz, Matthew D Alexander, Pavan Tirunahari Kumar, Mukta S Hendi, Yu-Hua Lee, Christopher A Benetatos, Guangyao Yu, Gurpreet Singh Kapoor, Eric Neiman, Martin E Seipel, Jennifer M Burns, Martin A Graham, Mark A McKinlay, Xiaochun Li, Jiawei Wang Show all

Journal of Medicinal Chemistry | AMER CHEMICAL SOC | Published : 2014

DOI: 10.1021/jm500176w

University of Melbourne Researchers

James Vince Author Medical Biology (W.E.H.I.)

John Silke Author Medical Biology (W.E.H.I.)

Rebecca Feltham Author Medical Biology (W.E.H.I.)

Grants

Awarded by NHMRC

Funding Acknowledgements

The authors acknowledge the support from our colleagues at TetraLogic Pharmaceuticals (Malvern, PA) and our co-workers at the START Preclinical Research Group (San Antonio, TX) and the Piedmont Research Center, LLC (Morrisville, NC) for conducting the animal experiments described in this paper. J.S. was supported by NHMRC grants (Grants 433013, 541902, 461221, 1046986) and fellowships (Grant 541901). C.L.D. acknowledges financial support from the Health Research Council of New Zealand. We thank C. Glenn Begley for critical reading of this manuscript.